Human American trypanosomiasis, commonly called Chagas disease, is one of the most neglected illnesses in the world and remains one of the most prevalent chronic infectious diseases of Latin America with thousands of new cases every year. The only treatments available have been introduced five decades ago. They have serious, undesirable side effects and disputed benefits in the chronic stage of the disease - a characteristic and debilitating cardiomyopathy and/or megavisceras. Several laboratories have therefore focused their efforts in finding better drugs. Although recent years have brought new clinical trials, these are few and lack diversity in terms of drug mechanism of action, thus resulting in a weak drug discovery pipeline. This fragility has been recently exposed by the failure of two candidates; posaconazole and E1224, to sterilely cure patients in phase 2 clinical trials. Such setbacks highlight the need for continuous, novel and high quality drug discovery and development efforts to discover better and safer treatments. In this article we will review past and current findings on drug discovery for Trypanosoma cruzi made by academic research groups, industry and other research organizations over the last half century. We also analyze the current research landscape that is now better placed than ever to deliver alternative treatments for Chagas disease in the near future.

Current and Future Chemotherapy for Chagas Disease / Gaspar, L.; Moraes, C. B.; Freitas Junior, L. H.; Ferrari, Stefania; Costantino, Luca; Costi, Maria Paola; Coron, R. P.; Smith, T. K.; Siqueira Neto, J. L.; Mckerrow, J. H.; Cordeiro da Silva, A.. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - STAMPA. - 22:37(2015), pp. 4293-4312. [10.2174/0929867322666151015120804]

Current and Future Chemotherapy for Chagas Disease

FERRARI, Stefania;COSTANTINO, Luca;COSTI, Maria Paola;
2015

Abstract

Human American trypanosomiasis, commonly called Chagas disease, is one of the most neglected illnesses in the world and remains one of the most prevalent chronic infectious diseases of Latin America with thousands of new cases every year. The only treatments available have been introduced five decades ago. They have serious, undesirable side effects and disputed benefits in the chronic stage of the disease - a characteristic and debilitating cardiomyopathy and/or megavisceras. Several laboratories have therefore focused their efforts in finding better drugs. Although recent years have brought new clinical trials, these are few and lack diversity in terms of drug mechanism of action, thus resulting in a weak drug discovery pipeline. This fragility has been recently exposed by the failure of two candidates; posaconazole and E1224, to sterilely cure patients in phase 2 clinical trials. Such setbacks highlight the need for continuous, novel and high quality drug discovery and development efforts to discover better and safer treatments. In this article we will review past and current findings on drug discovery for Trypanosoma cruzi made by academic research groups, industry and other research organizations over the last half century. We also analyze the current research landscape that is now better placed than ever to deliver alternative treatments for Chagas disease in the near future.
2015
22
37
4293
4312
Current and Future Chemotherapy for Chagas Disease / Gaspar, L.; Moraes, C. B.; Freitas Junior, L. H.; Ferrari, Stefania; Costantino, Luca; Costi, Maria Paola; Coron, R. P.; Smith, T. K.; Siqueira Neto, J. L.; Mckerrow, J. H.; Cordeiro da Silva, A.. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - STAMPA. - 22:37(2015), pp. 4293-4312. [10.2174/0929867322666151015120804]
Gaspar, L.; Moraes, C. B.; Freitas Junior, L. H.; Ferrari, Stefania; Costantino, Luca; Costi, Maria Paola; Coron, R. P.; Smith, T. K.; Siqueira Neto, J. L.; Mckerrow, J. H.; Cordeiro da Silva, A.
File in questo prodotto:
File Dimensione Formato  
33_CurrMedChem_2015_chagas_PDF Proof.pdf

Open access

Descrizione: bozza
Tipologia: Versione originale dell'autore proposta per la pubblicazione
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF Visualizza/Apri
gaspar2015.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 12.35 MB
Formato Adobe PDF
12.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
gaspar2015 1-10.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 6.16 MB
Formato Adobe PDF
6.16 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
gaspar2015 11-20.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 6.17 MB
Formato Adobe PDF
6.17 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1095134
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 42
social impact